You can’t win with the tabloids. You’re either too fat, too thin, or hiding a deadly secret. This week’s tabloids continue their obsession with the stars’ weight, led by the ‘National Enquirer’ and its team of reporters expertly trained by ...
Combined with Slip Rings, this interface technology enables OEMs to produce 360 degree HD video Pan/Tilt/Zoom (PTZ) cameras at substantially reduced cost THine Electronics, Inc. (Tokyo Stock Exchange ... President and CEO of CEL. …
The chief executive at Vienna-based biotechnology firm Cel-Sci has written periodic letters to shareholders ... it probably would submit the drug for regulatory approval. The company's stock has remained below a dollar for the past year, …
The stock touched a 52-week high of $45.20 in intra-day trading. News: No news Clinical Trials & Near-term Catalysts: -- Two phase III trials for Tab-cel intended to support approval in the treatment of rituximab-refractory Epstein-Barr Virus …
The stock has climbed 32 percent in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CEL at …
I can't give details of what we are doing, but I assure you that by the end o the year, the market will have some agreeable surprises from M-cel. The bonds will be sold through the Mozambique Stock Exchange (BVM). The BVM …
Reni Benjamin, an analyst at Raymond James & Associates Inc., downgraded Kite to hold on May 8, saying the commercial prospects for axi-cel in non-Hodgkin lymphoma had been largely priced into the stock. When Maxim Group …
Axi-cel is aimed at non-Hodgkin lymphomas ... 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, …